Search

Displaying results 2361 - 2370 of 7540 in total
  1. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … [A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.

    Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsSynonyms: 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
  2. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier. … The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.

  3. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas. … It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases.

  4. Drug

    Tuberculin purified protein derivative

    go.drugbank.com/drugs/DB11601
    Approved

    The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate

  5. Drug

    Thiosulfuric acid

    go.drugbank.com/drugs/DB09499
    ApprovedInvestigational

    Sodium thiosulfate is also used to reduce the risk of ototoxicity associated with [cisplatin]. … [L43337] When administered 6 hours after cisplatin chemotherapy, Sodium thiosulfate leads to a lower incidence of cisplatin-induced hearing loss among children without affecting its effectiveness.

  6. Drug

    Typha latifolia pollen

    go.drugbank.com/drugs/DB10860
    Approved

    Typha latifolia pollen is the pollen of the Typha latifolia plant. Typha latifolia pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  7. Drug

    Agrostis gigantea pollen

    go.drugbank.com/drugs/DB10403
    Approved

    Agrostis gigantea pollen is the pollen of the Agrostis gigantea plant. Agrostis gigantea pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Inland Grasses, Mixture of Standardized and Non-Standardized Southern GrassesCategories: Non-Standardized Pollen Allergenic Extract
  8. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. … compared to standard VRd therapy.

  9. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur. … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from

  10. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC